Shubham Pant, MD, Highlights Outcomes With Erdafitinib in Gastrointestinal Cancers


Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.

In an interview with CancerNetwork®, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlighted key findings from a basket trial presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that examined the use of erdafitinib (Balversa) in gastrointestinal (GI) cancers.


One is a basket trial for patients with FGFR alterations, [including] driver mutations or fusions, with [treatment with] a drug called erdafitinib, which is an FGFR inhibitor. We presented the data at this ASCO in which we did a basket trial in non-bladder cancers, [including] a lot of GI cancers, glioblastoma, and other cancers. What we saw was that there was an overall response rate in this unselected tumor agnostic population of about 30%. What was even more exciting was that our patients with cholangiocarcinoma had response rates of up to 50% and patients with pancreatic cancer—a very hard to treat malignancies [with] outcomes that are not that great—had response rates of 30%. We were very excited about presenting the data at ASCO.


Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol. 2022;40(suppl 16):3007. doi: 10.1200/JCO.2022.40.16_suppl.3007

Related Videos
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
Nurses should be educated on cranial nerve impairment that may affect those with multiple myeloma who receive cilta-cel, says Leslie Bennett, MSN, RN.
Treatment with cilta-cel may give patients with multiple myeloma “more time,” according to Ishmael Applewhite, BSN, RN-BC, OCN.
Nurses may need to help patients with multiple myeloma adjust to walking differently in the event of peripheral neuropathy following cilta-cel.
Administering neoadjuvant therapy to patients with colorectal cancer may help surgical oncologists attain a negative-margin resection.
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides